The ISN has added two new webinars to its Rare Kidney Disease Toolkit, focusing on immunoglobulin A nephropathy (IgAN) and C3 glomerulopathy (C3G). These expert-led sessions offer valuable insights into diagnosing, managing, and treating these rare but challenging kidney diseases. Watch "Advancements in C3 Glomerulopathy (C3G)," featuring David Kavanagh (UK), Alison Ma (Hong Kong), and...
Join Jonathan Barratt (UK) and Richard Lafayette (US) as they explore the challenges of treating patients with IgA nephropathy (IgAN), especially younger individuals. Listen here With new medications now available, navigating treatment options has become more complex. Professor Lafayette presents a compelling case study from his practice, highlighting the real-world challenges of managing IgAN. This podcast is...
ISN-ACT Global Trials Focus editorial team member Megan Borkum summarizes the design and outcomes of the latest ISN-ACT Global Trials Focus "Trial of the Month." The "Trial of the Month" is available in several languages, now including German. Read all global trial selections from the ISN-ACT initiative here. In addition, in the ISN 'Guide for Everyone' series, selected clinical trials...
Kidney International® Home Dialysis: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference In May 2021, KDIGO held a conference on expanding home dialysis emphasizing the need for policy alignment, resources, and shared decision-making between patients, care partners, and healthcare teams to improve access and use. The conference stressed the need to advocate for...
ISN-ACT Global Trials Focus editorial team member Neeru Agarwal summarizes the design and outcomes of one of the ISN-ACT Global Trials Focus's latest trial selections. Read all global trial selections from the ISN-ACT initiative here. The "trial of the month" is available in several languages. In addition, selected clinical trials are demystified for the layperson. Efficacy and safety...
Click on the image to expand This visual abstract was supported by an unrestricted educational grant from Chinook Therapeutics, a Novartis company.
ISN-ACT Global Trials Focus Subgroup member Anastasiia Zykova summarizes the design and outcomes of the team's latest "Trial of the Month." Stay updated on the latest research and developments in kidney care: Access the new selection of global trials from the ISN-ACT initiative here. The "Trial of the Month" is available in several languages. Sparsentan Versus Irbesartan...
The kidney is particularly susceptible to damage by complement. Activation of the complement system is tightly regulated by a series of soluble and membrane-bound proteins. Failure of these checking mechanisms is one of the major causes of complement-mediated kidney diseases. Evidence of specific complement activity has been identified in several kidney diseases, including IgA nephropathy,...
This visual abstract was supported by an unrestricted educational grant from Chinook Therapeutics, a Novartis Company.
Daniel O’Hara, ISN-ACT Global Trials Focus coordinator, summarizes the design and outcomes of the latest "Trial of the Month." Explore all the global trial selections for November and December here. The "Trial of the Month" is available in several languages. A Phase 2 Trial of Sibeprenlimab in Patients With IgA Nephropathy Mathur et al., N Engl J Med...
Kidney International® Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification This report proposes a two-step classification of membranous nephropathy (MN). Step one is identifying the target antigen based on a multistep algorithm. The second step is the search for a potential underlying disease or associated condition. The meeting consensus favored using an antigen-based...
Kidney International® Measuring Albuminuria or Proteinuria: Does One Answer Fit All? The authors review international guideline recommendations on measuring proteinuria and albuminuria and discuss contexts where the optimal measure of proteinuria is unclear or controversial. They discuss evidence to support current recommendations for choice of measure, including the clinical settings of glomerulonephritis, transplantation, and pregnancy. They also...
The latest findings on the pathogenesis and treatment of IgAN will be presented and discussed at the 17th International Symposium on IgA Nephropathy in Tokyo, Japan, from September 27-30, 2023. The ISN, the Japanese Society of Nephrology (JSN), and the Asian Pacific Society of Nephrology (APSN) will hold a joint session, "International Comparison, East...
Download This infographic was supported by an unrestricted educational grant from Travere Therapeutics
Watch the latest ISN video abstract from the @ISNeducation Social Media Team. Watch the video here. This video is based on a paper from Kidney International Reports: Antibody Guided Therapy In PLA2R-associated Membranous Nephropathy
IgA nephropathy is one of the most common glomerular diseases, worldwide. The diagnostic histologic hallmark is dominant or codominant IgA staining on kidney biopsy; however, patients may present with various clinical syndromes ranging from asymptomatic abnormalities noted on urinalysis, nephritic syndrome, nephrotic-nephritic syndrome to rapidly progressive glomerulonephritis with crescentic transformation. There is substantial heterogeneity in the...
Join the ISN Global Trials Focus (GTF) editorial team and researchers from the TESTING* study for a live audio discussion on the GTF project and the TESTING randomized clinical trial on oral methylprednisolone. Access the Twitter Space conversation here on November 17, 2022, at 10 p.m. CET. Scan the QR code in the image above to...
